PEER REVIEWED PUBLICATIONS: 75
Manuscripts: 60
1. Bature, F., Guinn, B.A. Pang, D. & Pappas, Y. (2017) Signs and symptoms preceding the diagnosis of Alzheimer’s disease: A Systematic scoping review of literature from 1937-2016. In Press, BMJ Open.
2. Brooks, S.E., Bonney, S., Lee, C., Publicover, A., Khan, G., Smits, E.L., Sigurdardottir, D., Arno, M., Li, D., Mills, K.I., Pulford, K., Banham, A.H., van Tendeloo, V., Mufti, G.J., Rammensee, H.G., Elliott, T.J., Orchard, K.H. & Guinn, B.A. (2015) Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. Public Library of Science One, 10, e0140483.
3. Hofmann, S., Hardwick, N.R., Malinovskis, A., Mead, A., Greiner, J. & Guinn, B.A. (2015) Analogue peptides for the immunotherapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 64, 1357-67.
4. Khan, G., Brooks, S.E., Mills, K.I. & Guinn, B.A. (2015) Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31-38.
5. Collin, J.F., Wells, J., Czepulkowski, B., Lyne, L., Duriez, P., Banham, A.H., Mufti, G.J. & Guinn, B.A. (2015) A novel zinc finger gene, ZNF465, is inappropriately expressed in presentation acute myeloid leukaemia cells. Genes, Chromosomes & Cancer, 54, 288-302.
6. Whelan, M.C., Casey, G., O. Larkin, J., Guinn, B.A., O’Sullivan, G.C., & Tangney, M. (2014) Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. Public Library of Science One, 9, e97602.
7. Khan, G., Denniss, F., Mills, K.I., Pulford, K. & Guinn, B.A. (2014) PASD1: a promising target for the immunotherapy of haematological malignancies. Journal of Genetic Syndromes & Gene Therapy, 4, 186. Invited review for a special issue on "Cancer Genetics".
8. Khan, G. & Guinn, B.A. (2013) PASD1 (Xq28). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 20, 630-632.
9. Guinn, B.A., Lee, C., Richardson, D. & Orchard, K. (2013) Tumor cells in multiple myeloma patients express carcinoembryonic-antigen-related cell adhesion molecule 1. Blood e-Letters.
10. Hardwick, N.R., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G.J., Stevenson, F.K. & Guinn, B.A. (2013) An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide. Cancer Immunity, 13, 16-26.
11. Stafford, R., Smith, V.A., Husmeier, D., Grima, T. & Guinn, B.A. (2013) Predicting ecological regime shift under climate change: new modelling techniques and potential of molecular-based approaches. Current Zoology, 59, 403-417.
12. Liberante, F.G., Pellagatti, A., Boncheva, V., Bowen, D.T., Mills, K.I., Boultwood, J. & Guinn, B.A. (2013). High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British Journal of Haematology, 162, 282-284.
13. Boncheva, V., Bonney, S.A., Brooks, S.E., Tangney, M., O’Sullivan, G., Mirnezami, A. & Guinn, B.A. (2013) New targets for the immunotherapy of colon cancer – does reactive disease hold the answer? Cancer Gene Therapy, 20, 157-168.
14. Lam, P., Khan, G., Stripecke, R., Hui, K.M., Kasahara, N., Peng, K.-W. & Guinn, B.A. (2013) The innovative evolution of cancer gene and cellular therapies. Cancer Gene Therapy, 20, 141-149.
15. Khan, G. & Guinn, B.A. (2012) SSX2IP Synovial Sarcoma, X breakpoint 2 interacting protein. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 16, 552-554.
16. Guinn, B.A., Lee, C.H., Richardson, D. & Orchard, K. (2011) Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma. European Journal of Haematology, 87, 554-555.
17. Smits, E., Lee, C., Hardwick, N., Brooks, S.E., van Tendeloo, V.F.I., Orchard, K.H. & Guinn, B.A. (2011) Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 60, 757-769.
18. Lee, C.H., Guinn, B.A., Brooks, S.E., Richardson, D. & Orchard, K. (2010) CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials. British Journal of Haematology, 149, 795-797.
19. Cheuk, A.T.C., Wells, J.W., Chan, L., Westwood, N.B., Berger, S.A., Yagita, H., Okumura, K., Farzaneh, F., Mufti, G.J. & Guinn, B.A. (2009) Anti-tumour immunity in a model of acute myeloid leukaemia. Leukemia and Lymphoma, 50, 447-454.
20. Kordasti, S.Y., Afzali, B., Lim, Z., Ingram, W., Hayden, J., Barber, L., Mathews, K., Chelliah, R., Guinn, B.A., Lombardi, G., Farzaneh, F., Mufti, G.J. (2009) IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome: Implications for the pathogenesis of MDS. British Journal for Haematology, 145, 64-72.
21. Guinn, B.A., Greiner, J., Schmitt, M. & Mills, K.I. (2009) Elevated expression of the leukaemia associated antigen SSX2IP predicts good survival in acute myeloid leukaemia patients who lack detectable cytogenetic rearrangements. Blood, 113, 1203-1204.
22. Mohamedali, A., Guinn, B.A., Sahu, S., Thomas, N.S.B. & Mufti, G.J. (2009) Serum profiling reveals distinctive proteomic markers in the serum from chronic myeloid leukaemia patients. British Journal of Haematology, 144, 263-265.
23. Cheuk, A.T.C. & Guinn, B.A. (2008) Immunotherapy of acute myeloid leukaemia: Developing a whole cell vaccine. Frontiers in Bioscience, 13, 2022-2029.
24. Guinn, B.A., Bullinger, L., Thomas, N.S.B., Mills, K.I. & Greiner, J. (2008) SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. British Journal of Haematology, 140, 250-251.
25. Greiner, J., Bullinger, L., Guinn, B.A., Dohner, H. & Schmitt, M. (2008) Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clinical Cancer Research, 14, 7161-7166.
26. Collins, S.A., Guinn, B.A., Harrison, P.T., Scallan, M.F., O’Sullivan, G.C. & Tangney, M. (2008) Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy? Current Gene Therapy, 8, 66-76.
27. Wells, J.W., Cowled, C.J., Darling, D., Guinn, B.A., Farzaneh, F., Noble, A. & Galea-Lauri, J. (2007) Semi-allogeneic dendritic cells induce antigen-specific T-cell activation which is not enhanced by concurrent alloreactivity. Cancer Immunology, Immunotherapy, 56, 1861-1873.
28. Guinn, B.A., Mohamedali, A., Mills, K.I. Czepulkowski, B., Schmitt, M. & Greiner, J. (2007) Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomarker Insights, 2, 69-79.
29. Breslin, A., Denniss, F.A.K. & Guinn, B.A. (2007) SSX2IP: An emerging role in cancer. Biochemical and Biophysical Research Communications, 363, 462-465.
30. Denniss, F.A.K., Breslin, A., Ingram, W.I., Hardwick, N.H., Mufti, G.J. & Guinn, B.A. (2007) The leukaemia associated antigen, SSX2IP, is expressed during mitosis on the surface of myeloid leukaemia cells. British Journal of Haematology, 138, 668-669.
31. Yang, Z., Wang, H., Zhao, J., Peng, Y., Wang, J., Guinn, B.A. & Huang, L. (2007) Recent developments in the use of adenovirus and immunotoxins in cancer gene therapy. Cancer Gene Therapy, 14, 599-615.
32. Guinn, B.A., Kasahara, N., Farzaneh, F., Habib, N.A., Norris, J.S. & Deisseroth, A.B. (2007) Recent advances and current challenges in tumour immunology and immunotherapy. Molecular Therapy, 15, 1065-1071.
33. Guinn, B.A., Mohamedali, A., Thomas, N.S.B. & Mills, K.I. (2007) Immunotherapy of myeloid leukaemias. Cancer Immunology, Immunotherapy, 56, 943-957.
34. Guinn, B.A., Tobal, K. & Mills, K.I. (2007) Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia. British Journal of Haematology, 136, 510-512.
35. Cheuk, A.T.C. & Guinn, B.A. (2007) A whole cell vaccine for acute myeloid leukaemia. Gene Therapy 2007, 220-229.
36. Guinn, B.A., Gilkes, A.F., Mufti, G.J., Burnett, A.K. & Mills, K.I. (2006) The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted sub-groups of presentation acute myeloid leukaemia. British Journal of Haematology, 134, 238-239.
37. Knights, A.J., Weinzierl, A.O., Flad, T., Guinn, B.A., Martin Deeg, M., Mueller, L., Mufti, G.J., Stevanovic, S., Pawelec, G. (2006) A novel MHC-associated Proteinase 3 peptide isolated from primary CML cells further supports the significance of this antigen for immunotherapy of myeloid leukaemias. Leukemia, 20, 1067-1072.
38. Chan, L., Hardwick, N.R., Guinn, B.A., Darling, D., Gäken, J., Galea-Lauri, J., Ho, A.Y., Mufti, G.J., Farzaneh, F. (2006) An immune edited tumour versus a tumour edited immune system: Prospects for the immune therapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 55, 1017-1024.
39. Cheuk, A.T.C., Chan, L., Czepulkowski, B., Berger, S.A., Yagita, H., Okumura, K., Farzaneh, F., Mufti, G.J. & Guinn, B.A. (2006) Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 55, 68-75.
40. Guinn, B.A., Bland, E.A., Lodi, U., Tobal, K., Liggins, A.P., Petter, S., Wells, J.W., Banham, A.H. & Mufti, G.J. (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications, 335, 1293-1304.
41. Guinn, B.A., Gilkes, A.F., Woodward, E., Westwood, N.B., Mufti, G.J., Linch, D., Burnett, A.K. & Mills, K.I. (2005) Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications, 333, 703-713.
42. Tomlin, J.L.,* Guinn, B.A.,* Penn, L.Z. & Berinstein, N.L. (2005) Bcl-2 and c-Myc co-operate in the Epstein-Barr virus-immortalised human B-cell line GM607 but do not confer tumourigenicity. Leukemia and Lymphoma, 46, 581-592. *Authors contributed equally to the work.
43. Liggins, A.P., Guinn, B.A., Hatton, C.S., Pulford, K.A. & Banham, A.H. (2004) Serologic detection of diffuse large B-cell lymphoma-associated antigens. International Journal of Cancer, 110, 563-569.
44. Cheuk, A.T.C., Mufti, G.J. & Guinn, B.A. (2004) Role of 4-1BB:4-1BBL in cancer immunotherapy. Cancer Gene Therapy, 11, 215-226.
45. Adams, S.P., Sahota, S.S., Mijovic, A., Czepulkowski, B., Padua, R.A., Mufti, G.J. & Guinn, B.A. (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia, 16, 2238-2242.
46. Guinn, B.A., Collin, J.F., Li, G., Rees, R.C. & Mufti, G.J. (2002) Optimised SEREX technique for the identification of leukaemia associated antigens. Journal of Immunological Methods, 264, 207-214.
47. Yu, W.H., Go, L., Guinn, B.A., Fraser, P.E., Westaway, D. & McLaurin, J. (2002) Phenotypic and functional changes in glial cells as a function of age. Neurobiology of Aging, 23, 105-115.
48. Guinn, B.A., Bertram, E.M., DeBenedette, M.A., Berinstein, N.L. & Watts, T.H. (2001) 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular Immunology, 210, 56-65.
49. Verkoczy, L.K., Guinn, B.A. & Berinstein, N.L. (2000) Characterization of the human B cell RAG-associated gene, hBRAG, as a B cell receptor signal-enhancing glycoprotein dimer that associates with phosphorylated proteins in resting B cells. The Journal of Biological Chemistry, 275, 20967-20979.
50. Guinn, B.A., Evely, R.S., Walsh, V., Gilkes, A.F., Burnett, A.K. & Mills, K.I. (2000) An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells. Leukemia and Lymphoma, 37, 393-404.
51. Guinn, B.A., DeBenedette, M.A., Watts, T.H. & Berinstein, N.L. (1999) 4-1BBL cooperates with B7-1 and B7-2 in converting a B-cell lymphoma cell line into a long-lasting antitumor vaccine. The Journal of Immunology, 162, 5003-5010.
52. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Petterssen, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 12, 887-892.
53. Fouillard, L., Matthews, K.E., Guinn, B.A., Branch, D.R. & Keating, A.K. (1998) Expression of factor IX cDNA introduced into human marrow stromal cells by electroporation. Hematology, 3, 347-354.
54. Guinn, B.A. & Mills, K.I. (1997) p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia. Leukemia and Lymphoma, 26, 211-226.
55. Guinn, B.A. & Padua, R.A. (1997) p53: A role in the initiation and progression of leukaemia? The Cancer Journal, 8, e195-200. Invited review.
56. Mills, K.I., Guinn, B.A., Walsh, V.A. & Burnett, A.K. (1996) Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leukemia Research, 20, 771-775.
57. Guinn, B.A., Al-Sabah, A.I., Hewlett, C. & Padua, R.A. (1995) Elevated levels of p53 protein in the neutrophils and monocytes of a patient with chronic idiopathic thrombocytopenic purpura or possible early myelodysplasia? Leukemia Research, 19, 727-731.
58. Guinn, B.A. & Padua, R.A. (1995) Do p53 mutations have a role in the initiation and progression of leukaemia? The Cancer Journal, 8, 195-200. Invited review.
59. Guinn, B.A., Smith, M.C., Padua, R.A., Burnett, A.K. & Mills, K.I. (1995) Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research, 19, 519-525.
60. Guinn, B.A., Padua, R.A., Burnett, A.K. & Mills, K.I. (1994) p53 mutations indicate a changing clonal evolution in a portion of chronic myelocytic leukaemia patients. Blood, 84, 3591.
Book Chapters: 5
1. Hofmann, S., Khan, G., Boncheva, V., Greiner, J. & Guinn, B.A. (2014) Vaccination against myeloid leukaemias using newly defined antigens. In Cancer Immunology Immunotherapy. (Ed. by Rees, R.) Oxford University Press. ISBN 978-0-19-967686-6.
2. Khan, G., Brooks, S.E., Denniss, F.K., Sigurdardottir, D. & Guinn, B.A. (2013) Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside. In Gene Therapy (Ed. by Wei, M. & Good, D.). IntechOpen. ISBN 980-953-307-743-2.
3. Guinn, B.A. & Tobal, K. (2007) Tumour antigens as markers of minimal residual disease in acute myeloid leukaemia. In Tumour Markers Research Perspectives (Ed. By Sinise, G.A.) pp. 77-90. Nova Science Publishers, Inc., New York., U.S.A.
4. Liggins, A., Guinn, B.A. & Banham, A.H. (2005) Identification of lymphoma-association antigens using SEREX. Methods in Molecular Medicine, 115, 109-128.
5. Padua, R.A., Taylor, C., Guinn, B.A., Baker, A., Warren, N., Bowen, D., Cachia, P., Culligan, D., Ridge, S., Carter, G., Hughes, D., White, D., Hoy, T., Burnett, A.K. & Jacobs, A. (1993) Genetic lesions in preleukaemias. In Molecular Biology of Haematopoiesis, 3, (Ed. by Abraham, N.G., Shadduck, R.K., Levine, A.S. & Takaku, F.) pp. 313-322. Intercept, Andover, U.K.
Editorials: 2
1. Guinn, B.A. (2015) Is there a need to identify novel tumour antigens as targets for immunotherapy clinical trials for the removal of minimal residual disease in haematological malignancies? Invited submission. International Journal for Haematological Research, 1, 24-26.
2. Guinn, B.A. (2014) The future of publishing scientific data: is it time to accept the wider publication of null data? Invited submission. EC Cancer, 1, 1-2.